An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
VERDICT
The label
Accumulation
read at $48.77
Novo Nordisk A/S holds its Accumulation at $48.77.
PHPhase · the trend structure carries the Accumulation label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-24
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 44 days
Price
$48.77
Valuation
11.67 trailing · 14.94 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.36
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 18% discount to our $57.51 fair value, 24.00% revenue growth.
Read at
$48.77
11.67 P/E · 14.94 fwd
Our fair value
$57.51
18% discount
Analyst target (avg)
$46.01
-6% to current
Target low $39.76Analyst target rangeTarget high $62.76
▲ current $48.77 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$48.77
you are here
Conservative
$53.87
+10%
Analyst avg
$46.01
-6%
Our fair value
$57.51
+18%
Analyst high
$62.76
+29%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Revenue growth
24.00%
Profit margin
37.21%
Debt to equity
72.09
Analyst consensus
Buy · 12 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✓ PASSES
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 24.1% of its assets, well under the one-third ceiling — it does not run on borrowed money. Against market value it is 67.9%, under the 30% line the market-value standard uses — so that standard clears it.Divergent
Interest-bearing cashCash held in interest-bearing accounts and securities is 4.9% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 1.1% of assets, under the 49% limit.Pass
Revenue purityOnly 1.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Weight loss drugs turning Danish pharma into cash engine
When patients finally get access to reliable weight loss or diabetes treatments the results show up fast in prescriptions and in revenue. Novo Nordisk sits at the centre of that demand with 24 percent revenue growth, 37 percent profit margins and 71 percent return on equity, all while trading at a forward multiple of 14.9 times and 15 percent below our fair value.
Those numbers explain why the shares look attractive despite a consensus target from twelve analysts that sits below the current price. The business passes our ethical screen cleanly and the underlying demand for its core products shows no sign of slowing.
Competition from newer entrants and any future pricing pressure remain real risks that could compress margins faster than growth can offset. Currency moves and regulatory shifts in key markets add further uncertainty. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Denmark and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
NVO trades on NYSE (ADR) (the company is based in Denmark). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (12 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis. Entered 2026-07-31 · Accumulation
JOURNAL
The dated journal · newest first, never edited
2026-07-31Accumulation$48.77+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (12 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-30Accumulation$48.77+11.1%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (12 analysts) rates it buy, with a mean price target of $47. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Accumulation$43.88+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (12 analysts) rates it buy, with a mean price target of $47.
2026-07-03Accumulation$43.88+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Accumulation$43.88Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$46.40
-7.8%
·
$922
-7.8%
2 months
$37.52
+14.0%
·
$1,140
+14.0%
3 months
$36.67
+16.6%
$1.28
$1,201
+20.1%
6 months
$48.51
-11.8%
$1.28
$908
-9.2%
1 year
$75.67
-43.5%
$1.86
$590
-41.0%
2 years
$134.33
-68.2%
$3.47
$344
-65.6%
3 years
$73.03
-41.4%
$4.84
$652
-34.8%
5 years
$37.93
+12.8%
$6.53
$1,300
+30.0%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever NVO does next, these words stay.
Novo Nordisk A/S · NVO · Accumulation · $48.77
Recorded 2026-07-24 · before the outcome · scored mechanically
